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While many genes have been investigated for their role in pancreatitis, few have
been conﬁrmed as risk factors in large cohort studies. Furthermore, pancreatitis
associated mutations in these genes are very rare, usually less than 3% in healthy
subjects and thus are not relevant for the majority of the patient population in North
America. Speciﬁcally, rare mutations in the trypsinogen gene (PRSS1) resulting in
uncontrolled trypsin activity lead to autosomal dominant hereditary pancreatitis
(HP). We hypothesize that common variations in PRSS1 may play a role in other
pancreatic etiologies as well.
We genotyped all cases and controls in the NAPS study for variations in PRSS1,
with complete data in 952 pancreatitis cases and 646 controls. We compared the
frequencies of common SNPs between controls and cases in groups with and
without genetic or environmental risk factors.
We identiﬁed 4 common SNPs that did not change the protein sequence, but formed
two frequent haplotypes that account for the majority of alleles (Hap1 60.5%, Hap2
35.4%). The Hap1 allele was identiﬁed more frequently in cases than controls
(OR 1.31 p = 0.001), and the Hap2 allele less frequently (0.71 p = 0.002). Hap2
carrier status was a signiﬁcant protective factor among the entire cohort, especially
against chronic disease and those with mutations in CFTR or SPINK1.
Pancreatic tissue samples with at least one Hap2 allele showed lower relative PRSS1
cDNA levels than Hap1 homozygotes, indicating that these haplotypes may result
in different trypsin expression levels.
We have identiﬁed a common PRSS1 haplotype that is a signiﬁcant protective factor
against genetic pancreatitis.
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Objectives: In this study we aim to identify novel genes involved in CF pathophys-
iology by applying a quantitative proteomics approach to compare the proteomes
of wild-type and F508del homozygous primary nasal and bronchial epithelial cells.
Methods: Nasal and bronchial epithelial cells, that are obtained by brushing with
small cytology brushes, are cultured and harvested at passage 1 or 2 for proteomic
analysis. Protein separation is performed by 2-D electrophoresis. Spots, representing
differences in relative protein amounts, are compared and identiﬁed by MALDI-
TOF MS.
Results: Preliminary experiments performed in our group comparing a wild-
type (16HBE14o−) and a F508del homozygous (CFBE41o−) cell line led to the
identiﬁcation of 7 proteins which are down-regulated and 4 proteins which are up-
regulated at least twofold in the CFBE41o− cell line. By now, we performed several
2-D proteomics gels of primary wild-type and F508del nasal and bronchial cells.
We were able to identify 61 protein spots by Maldi-TOF MS. Among them, the
protein sperm associated antigen 1 (SPAG1) was found to be present in F508del
proteomes but lacking in the wild-type proteomes. Characterization of differentially
expressed proteins is ongoing.
Conclusion: To our knowledge, this is the ﬁrst time that proteome analyses of
primary nasal and bronchial epithelial cells have been successfully established. We
already found one protein, SPAG1, that might be involved in CF pathogenesis. We
are looking for further differentially expressed proteins in CF cells that may help
to explain the phenotypic heterogeneity of the disease.
